GoodRx Holdings Inc. (NASDAQ:GDRX) saw its shares inch 1.7% higher in Monday’s premarket session after unveiling a pair of new initiatives designed to make GLP-1 weight-loss drugs more attainable for U.S. consumers.
The prescription-savings platform introduced GoodRx for Weight Loss, a subscription-based telehealth program that links users with licensed clinicians for obesity-care evaluations, prescriptions, and continued medical oversight. The service launches at a promotional rate of $39 per month through January 2026 before shifting to a standard $119 monthly fee, with medication costs billed separately.
Alongside the new program, GoodRx also revealed a partnership with Novo Nordisk (NYSE:NOV) that will provide first-time GoodRx customers access to Ozempic and Wegovy injection pens at a temporary out-of-pocket price of $199 per month. The offer covers the first two fills of the lowest available doses and then moves to a recurring price of $349 per month. The discount window runs through March 2026.
“GoodRx is scaling a consumer-first model for affordable GLP-1 treatment,” said Wendy Barnes, President and CEO of GoodRx. “We’re committed to connecting consumers with FDA-approved GLP-1 medications backed by science and safety, not compounded alternatives that fall short of those standards.”
Demand for GLP-1 medicines has surged as more patients seek medical support for chronic weight management, but affordability remains a major barrier without insurance. GoodRx’s dual launch aims to address that hurdle by bundling telehealth access with a temporary manufacturer-supported cash-price option.